In a controversial turn of events, Chinese scientist He Jiankui is attempting to reestablish himself in the field of gene editing following his imprisonment for creating...
Dyne Therapeutics announced on Monday that its experimental drug targeting Duchenne muscular dystrophy (DMD) has successfully met its primary endpoint in a late-stage clinical trial. This...
Dyne Therapeutics announced on October 16, 2023, that its experimental drug for **Duchenne muscular dystrophy** (DMD) has successfully met the primary endpoint in a late-stage clinical...
